Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the Uni...( PT. RICHMOND Calif....),Health

PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) will host a conference call to discuss its exclusive license and collaboration agreement with Purdue Pharmaceutical Products L.P. to commercialize Intermezzo((R)) (zolpidem tartrate sublingual tablet) in the United States. The FDA has established October 30, 2009 as the Prescription Drug User Fee Act (PDUFA) action date for the Intermezzo((R)) New Drug Application (NDA).

Conference Call Information

          Date: Monday, August 3, 2009
          Time: 8:30 a.m. ET
          Dial-in (U.S.): 877-545-1490
          Dial-in (International): 719-325-4864

A simultaneous web cast of the conference call will be available on the Investor Relations section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until Monday, September 7, 2009.

A telephone replay of the conference call will be available beginning August 3, 2009 at 11:30 a.m. ET and ending on August 17, 2009. The replay telephone number is 888-203-1112 (U.S.) or 719-457-0820 (International), Replay Passcode: 5541799.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. For further information, please visit the company's website at: www.transcept.com.

    Contacts:          Transcept Pharmaceuticals, Inc.
                       Greg Mann
                       Director of Corporate Communications
      
'/>"/>
SOURCE  Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 
Related medicine news :

1. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
2. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
3. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
4. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
5. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
6. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
7. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
8. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
9. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
10. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
11. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel